ARF gene product responds to oncogenic stresses by interfering with the inhibitory effects of Mdm2 on p53, thus enhancing p53 activity and its antiproliferative functions. The absence of p19 ARF in the mouse leads to early tumor susceptibility, presumably in part due to decreased p53 activity. To examine the tumorigenic cooperativity of p19 ARF , Mdm2, and p53 in vivo, p19 ARF -deficient mice were crossed first to p53-deficient mice and then to Mdm2 transgenic mice. The progeny were monitored for tumors. Cooperativity between p19 ARF and p53 deficiencies in accelerating tumor formation was observed for most genotypes except p53À/À p19 ARF À/À mice. p53À/À p19 ARF À/À mice had a tumor incidence similar to p53À/À mice. In this context, tumor suppression by ARF appears to be primarily p53 dependent. The majority of the p19 ARF þ /À tumors deleted the wildtype p19 ARF allele, in agreement with the previous studies, suggesting that p19 ARF is a classic 'two hit' tumor suppressor. In a p53 þ /À background, however, all p19 ARF þ /À tumors retained a wildtype ARF allele and most also retained wildtype p53. In the second cross between p19 ARF -deficient and Mdm2 transgenic mice, cooperativity in tumor incidence between Mdm2 overexpression and ARF deficiency was observed, consistent with the role of p19 ARF in negatively regulating Mdm2 activity. These experiments further demonstrate in vivo the inter-relationships of the p19 ARF -Mdm2-p53 signaling axis in tumor suppression.
Introduction
Mutations in the p53 tumor suppressor gene occur in roughly half of all human tumors and defective p53 signaling may occur in 80% or more of human cancers (Levine, 1997; Lozano and Elledge, 2000) . p53 protein is stabilized and activated as a result of a wide array of cellular stresses (Ljungman, 2000; Vogelstein et al., 2000; Vousden and Lu, 2002) . DNA damage generally stabilizes p53 through phosphorylation of serine and threonine residues in its amino and carboxyl domains (Ljungman, 2000; Appella and Anderson, 2001 ). Phosphorylation of amino-terminal serines of p53 by DNA damage-induced kinases prevents association with the E3 protein ligase Mdm2-and ubiquitin-mediated degradation of p53 (Alarcon-Vargas and Ronai, 2002; Michael and Oren, 2002) . This results in more activated p53, which can then transcriptionally regulate a number of cell growth-and apoptosis-associated genes, resulting in either cell cycle arrest or cell death.
Aberrant oncogenic signals can activate p53 through the p19 ARF pathway Sherr, 2001) . The levels of p19 ARF protein are increased following oncogenic signaling, as occurs with overexpression of c-myc or mutational activation of ras (Palmero et al., 1998; Zindy et al., 1998) . Increased ARF levels inhibit Mdm2-mediated proteolytic degradation of p53 Zhang et al., 1998) . Thus, ARF leads to increased levels of p53 and results in either p53-mediated cell cycle arrest or apoptosis. Such a pathway presumably serves to protect the organism from cells that initiate aberrant oncogenic signaling and might potentially develop into cancers (Sherr, 2001) .
The fact that ARF positively regulates p53 function implicates it as a potential tumor suppressor. ARF is part of a locus that includes it and another tumor suppressor, the cyclin-dependent kinase inhibitor p16 INK4a , in alternative reading frames. Deletions or silencing of the INK4a/ARF locus are frequently observed in human tumors (Kamb et al., 1994) . That both proteins are potent tumor suppressors is confirmed by the fact that inactivation of both or each individually results in early tumor formation in genetically modified mice (Serrano et al., 1996; Kamijo et al., 1997; Krimpenfort et al., 2001; . About 80% of p19 ARF -null mice develop tumors by 1 year of age, compared to 100% tumor development by 10 months of age in p53-null mice (Harvey et al., 1993; Kamijo et al., 1999) . ARF-null mice develop lymphomas and sarcomas, as do p53-null mice, but also exhibit many more carcinomas and nervous system tumors than are observed in p53-null mice. The p19 ARF þ /À mice develop tumors after a relatively long latency and tumor formation is associated with loss of the remaining wildtype allele or loss of its expression (Kamijo et al., 1999) . This suggests that ARF behaves as a classic 'two hit' tumor suppressor gene, although the possibility that it may in some instances be haploinsufficient for tumor suppression was not ruled out.
An important question is whether ARF has p53-independent effects in tumor suppression. Recent experiments by Weber et al. (2000) indicate that this may be the case. Mice null for both ARF and p53 or for ARF, Mdm2, and p53 develop tumors at about the same rate as p53-null mice, but exhibit a spectrum of tumors broader than that of p53-null animals. Moreover, ARF introduced into mouse embryo fibroblasts lacking p53, Mdm2, and endogenous ARF restores a partial G1 arrest function, suggesting the presence of p53-independent cell cycle regulatory targets for ARF. Subsequent studies have tended to confirm a p53-independent role for ARF in tumor suppression, growth arrest, and apoptosis induction (Tsuji et al., 2002; Eymin et al., 2003; Kuo et al., 2003) , although another recent study argued that G1 and G2 arrest functions of ARF required p53 in several human cell types (Weber et al., 2002) .
ARF increases p53 activity primarily through its inhibition of Mdm2 (Sherr, 2001) . Mdm2 is also inhibited following DNA damage through phosphorylation by ATM (Appella and Anderson, 2001; AlarconVargas and Ronai, 2002) . Thus, both DNA damage and aberrant oncogenic signaling can regulate p53 through effects on Mdm2 activity. The primary role of Mdm2 during development is to modulate p53 activity, since the absence of Mdm2 in the mouse leads to embryonic lethality, which can be rescued by removal of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995) . Double null p53/Mdm2 mice develop normally but succumb to tumors of the same type and at the same rate as p53-null animals. Interestingly, p53-null, Mdm2 heterozygous mice showed a delayed tumorigenesis and increased sarcoma formation compared to p53-null mice (McDonnell et al., 1999) . This increased sarcoma incidence was also observed in transgenic mice globally overexpressing Mdm2 , consistent with the fact that amplification of Mdm2 has been associated with a fraction of human sarcomas (Leach et al., 1993) . Mammary gland-specific overexpression of Mdm2 leads to cell cycle disruption, and aberrant mammary gland morphology (Reinke et al., 1999) . In the absence of 19 ARF , the aberrant histopathologies were accentuated, indicating that p19 ARF and Mdm2 cooperate to disrupt cell cycle control and mammary gland development (Foster and Lozano, 2002) .
In this paper, we further explore the interactions of 19 ARF , Mdm2, and p53 in tumor development through the use of crosses between p53-and ARF-deficient mice or between ARF-deficient mice and Mdm2-overexpressing transgenic mice. We found that p19 ARF deficiency can accelerate tumorigenesis in a dose-dependent manner when one or two copies of p53 are present, but appears to have little or no effect on tumor incidence when p53 is absent. This suggests that the primary effect of ARF in tumorigenesis is through p53, although p53-independent effects cannot be ruled out. We also found that tumors p19 ARF þ /À mice often exhibit loss of the wildtype allele, suggesting that p19 ARF behaves as a classic 'two hit' tumor suppressor in most contexts. In the p19 ARF -Mdm2 transgenic crosses, we saw a dosedependent cooperation between p19 ARF deficiency and Mdm2 overexpression in all cases, consistent with the critical role of p19 in regulating Mdm2 activity.
Results
Tumor incidence and spectra of p53/p19 ARF -deficient mice
To assess cooperativity in tumorigenesis between p19 ARF and p53, p19 ARF -deficient mice were crossed to p53-deficient mice. Since both p53-and p19 ARF -null mice are viable, nine different p19 ARF /p53 genotype combinations were obtained and these mice were monitored up to 2 years for tumors. Mice that were wild type for p19 ARF , but with varied p53 genotypes, showed tumor incidence curves roughly similar to those observed historically for p53 þ / þ , p53 þ /À, and p53À/À mice (Venkatachalam et al., 2001) (Figure 1a ). Mice that were wild type for p53, but variable for the three possible p19 ARF genotypes were also monitored for tumors up to 2 years. All p19À/ À mice succumbed to tumors by 75 weeks of age, while 80% of p19 ARF þ /À mice developed tumors or died by 104 weeks of age ( Figure 1b ). This incidence was significantly different than the 20% tumor/death incidence in wildtype mice by 104 weeks of age as measured by log-rank test (Po0.0001). Thus, 19 ARF heterozygotes show significantly enhanced tumor susceptibility compared to wildtype animals, confirming and extending the p19 ARF þ /À tumor incidence results first reported by Kamijo et al. (1999) .
When the p19 ARF þ /À mice were compared for tumor incidence in the context of different p53 dosages, reduction of p53 resulted in a greatly accelerated tumor incidence in a dosage-specific manner ( Figure 1c ). p19 ARF À/À mice also exhibited significantly enhanced tumorigenesis in the presence of p53 heterozygosity compared to their p19À/À p53 þ / þ counterparts ( Figure 1d ). Tumor incidence in the p19 ARF À/À mice was even further accelerated in the absence of p53 ( Figure 1d ).
When p53 þ /À mice of variable p19 ARF genotypes were compared, reduction of p19 ARF resulted in a significant acceleration of tumorigenesis only in the p53 þ /À p19 ARF À/À mice (P ¼ 0.0001) (Figure 1e ). The p53 þ /À p19 ARF þ /À and p53 þ /À p19 ARF þ / þ survival curves were virtually superimposable and were not significantly different by log-rank test (P ¼ 0.53) (Figure 1e ). However, when p53À/À mice of varying p19 ARF dosage were monitored for tumors, significant differences in tumor incidences were not observed among any of the p53À/À curves as measured by log-rank test (Figure 1f ). This may in part be due to the low numbers of p53À/À p19 ARF þ / þ mice monitored, but when historical p53À/À curves are compared to the p53À/À p19 ARF À/À curves, no significant statistical differences were detected, indicating that tumor incidence in p53À/À mice is not greatly influenced by p19 ARF status. This is consistent with the results previously reported by Weber et al. (2000) and suggests that the primary role of p19 ARF in influencing tumor onset is through its effects on p53 function.
Tumors were harvested from all genotypes of p19 ARF / p53-deficient mice and subjected to histopathological analyses to identify tumor types. All genotypes exhibited a high number of lymphomas (Table 1) . These were frequently of generalized lymphoma type that primarily affected the spleen and lymph nodes with spreading to other tissues. Most genotypes (except for the p53 þ /À p19 ARF þ / þ mice) exhibited more lymphomas than any other tumor type. The other predominant tumor type was sarcoma, with osteosarcomas and fibrosarcomas occurring quite often. Carcinomas were rarely observed except for the p53 þ / þ p19 ARF þ /À mice, which displayed four such tumors, including three lung adenocarcinomas. Only one soft-tissue sarcoma and one osteosarcoma were observed in the p53 þ / þ p19 ARF þ /À mice, consistent with low sarcoma incidence in p19 ARF þ /À mice reported by Kamijo et al. (1999) . Mice null for p19 exhibited more lymphomas than sarcomas and only one astrocytoma was observed in a p53 þ /À p19 ARF À/À mouse, in contrast to more frequently observed sarcomas and nervous system tumors in p19 ARF À/À reported by Kamijo et al. (1999) . The preponderance of lymphomas in almost all genotypes was not unlike that observed in wildtype mice of the same background (Table 1) (Venkatachalam et al., 2001) . This suggests that in this cohort of animals most of the effects of p19 and p53 deficiency may have been able to accelerate the formation of tumor types to which this strain background was already predisposed.
p53 and p19 ARF allele loss in heterozygous tumors
The p19 ARF heterozygote mice had a significantly enhanced tumor incidence relative to wildtype mice, consistent with the role of p19 ARF as a tumor suppressor. The 'two hit' model for tumor suppressors would predict that p19 ARF þ /À tumors would exhibit loss or mutation of the remaining wildtype ARF allele or downregulation of its expression (Knudson, 1984) . Alternatively, like some other tumor suppressors, p19 ARF could be haploinsufficient for tumor suppression (Fero et al., 1998; Venkatachalam et al., 2001; Bai et al., 2003) . We have previously shown that over half of p53 þ /À tumors retain a structurally and functionally intact wildtype p53 (Venkatachalam et al., 1998 (Venkatachalam et al., , 2001 ). When we examined p53 þ /À tumors that were also ARF þ /À or ARFÀ/À, we found that the majority of these cancers did retain their wildtype p53 allele (Figure 2a) . After Southern blot hybridization analysis of p53 allele status, six of 11 p53 þ /À p19 ARF þ /À tumors (55%) appeared to retain a wildtype p53 allele, while 12 out of 17 p53 þ /À p19 ARF À/À tumors (71%) retained a wildtype p53 allele.
To examine p19 ARF allele status in p19 ARF þ /À tumors, we performed Southern blot hybridization on tumor DNAs from p19 ARF þ /À tumors of p53 þ /À and p53 þ / þ genotypes. Of the 18 p53 þ /À p19ARF þ /À tumors examined, all appeared to retain the wildtype ARF allele (Figure 2b ). When nine p53 þ / þ p19ARF þ /À tumors were examined, three tumors retained their wildtype ARF allele, but six tumors appeared to lose the wildtype ARF allele (Figure 2c) partially or fully. Partial loss of wildtype ARF (wildtype allele visible but exhibits less than 50% of mutant ARF band intensity) is categorized as 'loss of heterozygosity (LOH)' and is likely to be due to either normal tissue contamination of tumor samples or to loss of the wildtype allele in a majority, but perhaps not all, of the tumor cells within the tumor. Despite the apparent retention of the wildtype ARF allele in some of the p53 þ / þ p19ARF þ /À tumors, it is possible that expression of wildtype ARF is downregulated or that it is expressed but has incurred an inactivating point mutation. However, in two-thirds of the tumors the wildtype ARF allele is clearly lost, supporting the idea that loss of both ARF alleles is usually a prerequisite for tumor formation.
Tumor incidence and spectra of p19 ARF deficient/Mdm2 transgenic mice
In a second study, we assessed the cooperativity of p19 ARF and Mdm2 in tumorigenesis. The p19 ARFdeficient mice were crossed to Mdm2 transgenic mice. The Mdm2 transgenic mice contained multiple copies of a wildtype Mdm2 genomic clone under the control of its own promoter . The Mdm2 transgenic mice express roughly fourfold increased Mdm2 RNA throughout many of their tissues and have an accelerated tumor incidence compared to wildtype mice of the same background . When p19 ARF deficiency was introduced into the Mdm2 transgenics, tumor incidence was significantly accelerated (Figure 3a) . p19 ARF þ / þ Mdm2 TG mice in this study showed accelerated tumorigenesis compared to their wildtype nontransgenic counterparts (Figure 3b ), similar to previous findings . Logrank comparison of the two survival curves indicated that the differences were significant (P ¼ 0.018). Moreover, p19 ARF þ /À Mdm2 transgenic mice develop tumors significantly sooner than p19 ARF þ /À mice (Figure 3c ). Log-rank tests on these Kaplan-Meier plots showed a highly significant difference between the two genotypes (Po0.0001). Finally, p19 ARF À/À Mdm2 transgenic mice develop tumors at an accelerated rate compared to their p19 ARF À/À counterparts (Figure 3d) . Log-rank analysis revealed that the differences in tumor incidence were significant (P ¼ 0.017). Thus, it is clear that ARF deficiency cooperates with Mdm2 overexpression to promote accelerated tumor formation. This result is consistent with the proposed role of ARF in inhibiting Mdm2 function.
Analysis of the histopathology of the tumors in six different p19 ARF Mdm2 genotypes revealed again that the predominant tumor observed was a lymphoma (Table 2 ). In every genotype category examined, at least 70% of tumors were lymphoid in origin. Generally, these lymphoid tumors were similar in histopathology to p19 ARF deficient and p53 þ /À lymphomas and were particularly obvious by their infiltration of spleen and lymph nodes. Thymic lymphomas were relatively rare. Soft-tissue sarcomas (usually fibrosarcomas) were also observed in the various Mdm2 transgenic categories, although the number of tumors analysed for a particular genotype were not always sufficient to develop a complete picture of the tumor spectrum.
ARF protein has been shown to sequester or inhibit Mdm2 protein function Sherr, 2001) . To determine whether ARF status affected Mdm2 protein levels during tumorigenesis, we examined Mdm2 protein levels in Mdm2 tumor lysates that were p19 ARF þ / þ or p19 ARF À/À by immunoblot analysis. There appeared to be no obvious differences in Mdm2 protein levels in the presence and absence of Mdm2 (data not shown), suggesting that ARF deficiency did not necessarily affect Mdm2 protein levels.
Discussion
The ARF-Mdm2-p53 pathway is critical for the cellular response to aberrant oncogenic signaling. The experiments described here were designed to investigate the cooperativity and interactions of these pathway members during tumorigenesis in an intact organism. From previous experiments, it was known that reduction (ARF, p53) or increases (Mdm2) in dosage of individual pathway members resulted in earlier tumor susceptibility (Harvey et al., 1993; Jones et al., 1998; Kamijo et al., 1999) . Comparison of tumor incidence curves of p53 and p19 ARF singly deficient homozygous and heterozygous mice indicate that p53 is a much more potent tumor suppressor than ARF. This effect is confirmed in the bideficient ARF-p53 mice. For example, reduction of p53 dosage in ARF þ /À mice has a more accelerating effect on tumor incidence than reduction of ARF dosage in p53 þ /À mice (compare Figure 1c-e) . Yet, the absence of ARF in the p53 þ /À background significantly shortens tumor latency, consistent with models that loss of ARF should increase Mdm2 inhibition of p53. In the absence of p53, the presence or absence of ARF appears to have no significant effect on tumor latency (Figure 1f ), in agreement with results from Weber et al. (2000) , who showed similar survival curves in p53-null and p53/ ARF-double-null mice. However, they did observe a wider spectrum of tumor types in their double-null mice than in p53-null mice, suggesting a p53-independent role for ARF. While we were unable to observe an altered tumor spectrum in our p53/ARF double-null mice compared to p53-null mice (Table 1) , this may have been due to the relatively low number of double-null animals we analysed. With respect to tumor spectrum, most tumors were lymphomas, soft-tissue sarcomas, or osteosarcomas, and alterations in ARF dosage did not seem to affect tumor spectrum, with one exception. Heterozygosity in ARF resulted in greater numbers of carcinomas and fewer sarcomas compared to p53 heterozygotes, in agreement with results observed earlier by Kamijo et al. (1999) for p19 ARF þ /À mice. Early data from Kamijo et al. (1999) showed data that ARF heterozygote tumors lost their remaining wildtype ARF allele, but because of the low number of tumors analysed, the authors left open the possibility that ARF haploinsufficiency could not be formally ruled out. In other studies, lymphoma susceptible myc transgenic mice heterozygous for ARF displayed 80% LOH of ARF in their lymphomas (Eischen et al., 1999) . In Rb þ /À ARF þ /À pituitary tumors two out of six tumors exhibited ARF LOH (Tsai et al., 2002) . Our analysis of ARF heterozygote tumors indicated that two-thirds of p19ARF þ /À tumors exhibited LOH, largely confirming the findings of previous studies (Eischen et al., 1999; Kamijo et al., 1999; Tsai et al., 2002) . These results together indicate that ARF Cooperativity of p19 ARF , Mdm2, and p53 L Moore et al generally behaves as a classical 'two hit' tumor suppressor in the mouse and that loss of both alleles is a prerequisite for cancer progression. Interestingly, this ARF wildtype allele loss was absent in p53 þ /À tumors, indicating that selection for wildtype ARF loss is negligible when p53 dosage is reduced. While the absence of selection for ARF allele loss could be due to epigenetic silencing, we believe this mechanism is not operative in our tumors because all tumors examined exhibited robust wildtype ARF RNA expression (L Moore, data not shown). We hypothesize that p53 is such a potent tumor suppressor in mice that only a halving of its normal dosage is a major tumor promoting event, while ARF is a weaker tumor suppressor that requires loss of both alleles for only a moderate tumor promoting effect.
The role of ARF protein in inhibiting Mdm2 protein function has been clearly demonstrated in vitro and in some in vivo contexts (Tao and Levine, 1999; Weber et al., 1999; Sherr, 2001; Foster and Lozano, 2002) . We have shown here that overexpression of the Mdm2 transgene cooperates with ARF deficiency to accelerate tumor formation (Figure 3) . In ARF-null, heterozygous and wildtype animals, the presence of the Mdm2 transgene significantly decreases tumor latency ( Figure  3b-d) . These effects on tumorigenesis are consistent with the model that reduction of ARF protein increases the level of Mdm2, which is available for p53 inactivaction. ARF may sequester Mdm2 in cellular compartments (e.g. the nucleolus) where it can no longer interact with p53 and induce its degradation rather than reduce absolute levels of Mdm2 protein. This may explain why we were unable to detect consistent increases in Mdm2 protein levels in tumors missing ARF. The ability of overexpressed Mdm2 to accelerate tumorigenesis even in the absence of ARF suggests either that Mdm2 promotes cancer in ways independent of its degradation of p53 or that Mdm2 attenuates ARF-independent pathways of p53 stabilization. Simultaneous occurrence of ARF loss and Mdm2 amplification and overexpression has previously been observed in murine lymphomas and in soft-tissue sarcomas (Eischen et al., 1999; .
The results presented here provide further evidence of the interactions among the ARF, Mdm2, and p53 genes in the prevention of cancer in a model organism. The two important tumor suppressors, p53 and ARF, cooperate in tumorigenesis, but p53 is clearly a much more potent tumor suppressor than ARF. In the absence of p53, variation in ARF dosage appears to have little effect, consistent with data that ARF effects are primarily p53 dependent. In contrast, ARF-null mice are still profoundly affected by variation in p53 dosage, indicating that p53 is downstream of multiple pathways that feed into it to prevent cancer. The modest effects of Mdm2 overexpression with varying ARF dosages suggest more subtle effects of ARF and Mdm2 on p53 regulation. Further studies should uncover other pathways that regulate p53 activity in the suppression of cancer.
Materials and methods
Mice ARF-deficient mice in a C57BL/6 Â 129Sv background were generously provided by Martine Roussel. p53-deficient mice and Mdm2 transgenic mice were also on a mixed C57BL/ 6J Â 129Sv EvBrd background, but had been backcrossed at least four generations from the 129 background onto the C57BL/6J background. The generation and characterization of these mice have been described previously (Donehower et al., 1992; Kamijo et al., 1997; Jones et al., 1998) . p19 ARF þ /À mice were crossed to p53 þ /À and the doubly heterozygous offspring were mated to generate progeny of the nine possible combined ARF/p53 genotypes. These offspring were genotyped by Southern blot hybridization analysis of tail DNA samples with both ARF and p53 probes as previously described (Donehower et al., 1992; Kamijo et al., 1997 ). The genotyped mice were then monitored up to the age of 24 months for tumors, death, or morbidity. Morbid or tumor bearing animals were necropsied according to standard protocols and carefully examined for neoplastic lesions. Those dead animals with low levels of tissue autolysis were also subjected to pathological examination. Part of each tumor or tumor-like lesion was placed in formalin for histopathological analysis and another part was flash frozen for molecular analyses. Formalin-fixed tumor fragments were paraffin-embedded and hematoxylinand eosin-stained tumor sections were analysed by standard procedures. Ages of death or morbidity due to tumors were recorded and Kaplan-Meier survival plots calculated using Statview 5.0 (SAS).
Analysis of ARF and p53 allele status in ARF/p53-deficient tumors
High molecular weight DNA from tumors that were heterozygous for ARF or p53 or both genes was prepared as previously described (Venkatachalam et al., 1998) . Tumor DNAs were cleaved with BamHI (p53 þ /À tumors) or BfrI (ARF þ /À tumors), subjected to agarose-gel electrophoresis and Southern blot hybridization with p53 and ARF probes as previously described (Donehower et al., 1992; Kamijo et al., 1997) .
